Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest Amgen Stories

2013-12-19 08:28:17

Study Meets Primary Endpoint of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Dec. 19, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 DESCARTES (Durable Effect of PCSK9 Antibody CompARed wiTh PlacEbo Study) study evaluating the long-term 52-week safety and efficacy of evolocumab for the treatment of high cholesterol met its primary endpoint of percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 52. The mean percent...

2013-12-17 16:23:46

Helen Torley to assume role of President and CEO; Gregory I. Frost to lead Intrexon's Health Sector and will remain on Halozyme's Scientific Advisory Board SAN DIEGO, Dec. 17, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that Helen Torley, M.B. Ch. B., M.R.C.P., will be joining Halozyme as President and Chief Executive Officer on January 6, 2014. She will also become a member of Halozyme's Board of Directors. Dr. Torley was most recently Executive...

2013-12-17 12:26:14

BETHESDA, Md., Dec. 17, 2013 /PRNewswire-USNewswire/ -- The Parenteral Drug Association announced the results of its 2014 Board of Directors and Officers Elections. All those elected begin their terms in January 2014. (Logo: http://photos.prnewswire.com/prnh/20130226/DC66667LOGO) Executive CommitteeHal Baseman, who served as chair elect, assumes the role of PDA Chairman of the Board for the term from 2014-2016. Martin VanTrieste, Sr. Vice President, Quality, Amgen, was elected...

2013-12-17 08:30:23

Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Dec. 17, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 MENDEL-2 (Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2) trial with evolocumab met its co-primary endpoints: the percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 12 and the mean percent reduction from...

2013-12-13 16:24:28

THOUSAND OAKS, Calif., Dec. 13, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the first quarter of 2014. The dividend will be paid on March 7, 2014, to all stockholders of record as of the close of business on Feb. 13, 2014. About AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative...

2013-12-10 23:20:12

Reportbuyer.com just published a new market research report: Biosimilar Opportunities in an Evolving Market. London (PRWEB) December 10, 2013 Biosimilars: another milestone passed At the end of June 2013, the European Medicines Agency’s Committee for Medical Products for Human Use issued a positive opinion for the first biosimilar version of Johnson & Johnson’s infliximab for the treatment of rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. For the two...

2013-12-10 16:24:25

THOUSAND OAKS, Calif., Dec. 10, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will hold a post American Society of Hematology (ASH) summary webcast on Wednesday, Dec. 11, 2013, at 11 a.m. PST. Pablo Cagnoni, M.D., president of Onyx Pharmaceuticals, Inc. and Anthony C. Hooper, executive vice president of Global Commercial Operations at Amgen, will participate in the call to discuss a brief summary of data presented at...

2013-12-05 23:04:28

Reportbuyer.com just published a new market research report: Drug Delivery Partnering Terms and Agreements. London (PRWEB) December 05, 2013 The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals....

2013-12-05 16:25:15

THOUSAND OAKS, Calif., Dec. 5, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will participate at the Oppenheimer 24(th) Annual Healthcare Conference on Tuesday, Dec. 10, 2013, at the Crowne Plaza in New York City, beginning at 9:45 a.m. Eastern Standard Time. Arvind Sood, vice president of Investor Relations at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the...

2013-12-03 11:15:50

Findings to help physicians guide treatment options for women A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic acid caused more flulike symptoms. These findings were presented recently at the American Society for Bone and Mineral Research’s annual meeting. Researchers performed a retrospective chart review and...